Sadat-Ali Mir, AlShammari Sulliman M, Uddin Fares Z, Alani Fawaz M, Dahduli Omar S
1 Department of Orthopedic Surgery, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam and King Fahd Hospital of the University, Al-Khobar, Saudi Arabia.
2 King Hamad University Hospital, Bahrain.
J Int Med Res. 2019 May;47(5):1843-1847. doi: 10.1177/0300060518819630. Epub 2019 Jan 7.
The objective of this study was to identify deficiencies in initiating anti-osteoporotic treatment following a fragility femoral fracture.
All patients ≥55 years of age treated for a fragility femoral fracture between June 2012 and May 2017 were enrolled. Medications at discharge and at 90 days and 1 year of follow up were analyzed. Patients were classified into 4 groups: Group I did not receive any treatment for osteoporosis; Group II received only calcium and vitamin D; Group III received an anabolic agent, calcium, and vitamin D; and Group IV received bisphosphonates, calcium, and vitamin D.
A total of 167 patients with an average age of 65.81±12.55 years were included. There were 88 (52.7%) males and 79 (47.3%) females. At discharge, 107 patients (64.1%) were not prescribed optimal treatment for osteoporosis, and this reduced to 55 (32.9%) at the 90-day follow up. At 1 year, the number of patients receiving suboptimal treatment was further reduced to 25.74%.
Although the number of patients with fragility fractures receiving insufficient treatment was lower in the present study than in previous reports, increased efforts and coordinated treatment plans initiated by a fracture liaison service should be of high priority.
本研究的目的是确定股骨脆性骨折后启动抗骨质疏松治疗方面的不足。
纳入2012年6月至2017年5月间所有因股骨脆性骨折接受治疗的≥55岁患者。分析出院时、随访90天和1年时的用药情况。患者分为4组：I组未接受任何骨质疏松治疗；II组仅接受钙和维生素D治疗；III组接受促合成代谢药物、钙和维生素D治疗；IV组接受双膦酸盐、钙和维生素D治疗。
共纳入167例患者，平均年龄65.81±12.55岁。男性88例（52.7%），女性79例（47.3%）。出院时，107例患者（64.1%）未接受骨质疏松的最佳治疗，在90天随访时降至55例（32.9%）。在1年时，接受次优治疗的患者数量进一步降至25.74%。
尽管本研究中接受治疗不足的脆性骨折患者数量低于既往报告，但骨折联络服务加大力度并启动协调治疗计划应成为高度优先事项。
